In the GeparTrio trial (NCT00544765), a phase III randomized neoadjuvant study for breast cancer treatment, immunohistochemistry was used to examine the expression of GCDFP-15 (known as PIP) in 602 pre-therapeutic core biopsies obtained from patients [5]. This evidence concerns the gene PIP and breast carcinoma.